uniQure/$QURE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Ticker
$QURE
Sector
Primary listing
Employees
221
Headquarters
Website
uniQure Metrics
BasicAdvanced
$1.7bn
-
-$3.49
-
-
Price and volume
Market cap
$1.7bn
52-week high
$71.50
52-week low
$8.73
Average daily volume
1.8m
Financial strength
Current ratio
10.402
Quick ratio
9.969
Long term debt to equity
363.368
Total debt to equity
365.371
Interest coverage (TTM)
-2.98%
Profitability
EBITDA (TTM)
-168.534
Gross margin (TTM)
-613.92%
Net profit margin (TTM)
-1,154.42%
Operating margin (TTM)
-1,004.38%
Effective tax rate (TTM)
-2.77%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-16.41%
Return on equity (TTM)
-228.24%
Valuation
Price to revenue (TTM)
91.589
Price to book
11.67
Price to tangible book (TTM)
31.97
Price to free cash flow (TTM)
-9.603
Free cash flow yield (TTM)
-10.41%
Free cash flow per share (TTM)
-2.88
Growth
Revenue change (TTM)
-10.44%
Earnings per share change (TTM)
-20.15%
3-year revenue growth (CAGR)
-45.21%
10-year revenue growth (CAGR)
2.89%
3-year earnings per share growth (CAGR)
1.32%
10-year earnings per share growth (CAGR)
-0.86%
What the Analysts think about uniQure
Analyst ratings (Buy, Hold, Sell) for uniQure stock.
uniQure Financial Performance
Revenues and expenses
uniQure Earnings Performance
Company profitability
uniQure News
AllArticlesVideos
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp·4 weeks ago
QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Newsfile Corp·4 weeks ago
QURE DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE
Newsfile Corp·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for uniQure stock?
uniQure (QURE) has a market cap of $1.7B as of May 09, 2026.
What is the P/E ratio for uniQure stock?
The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of May 09, 2026.
Does uniQure stock pay dividends?
No, uniQure (QURE) stock does not pay dividends to its shareholders as of May 09, 2026.
When is the next uniQure dividend payment date?
uniQure (QURE) stock does not pay dividends to its shareholders.
What is the beta indicator for uniQure?
uniQure (QURE) does not currently have a Beta indicator.